Pattern and factors associated with glycemic control of Saudi diabetic patients.

Ann Saudi Med

Department of Medicine, King Khalid University Hospital, Department of Biochemistry, King Saud University, and Department of Preventive Medicine, Ministry of Health, Riyadh, Saudi Arabia.

Published: October 2012

Background: The pattern and factors which can be associated with the glycemic control of Saudi adult diabetic patients were examined in this study.

Patients And Methods: Confirmed diabetic patients from all regions of Saudi Arabia constituted the study population. Random blood glucose <10 mmol/L and >10 mmol/L was used to categorize patients into good and poor glycemic control patients, respectively.

Results: There were 613 confirmed non-insulin dependent diabetic patients (NIDDM), 50% with good glycemic control. Patients with poor glycemic control were significantly older than patients with good glycemic control (51.5 vs. 47 years, P=0.0001). The insulin-treated diabetic population amounted to 13%, compared with 43% and 44% for oral agent and diet, respectively. The rate of insulin users among poor glycemic control diabetic population was 18%, compared with 50% for oral agents. There was a significant relationship between glycemic control and age, and treatment modalities of DM. Subjects who had good glycemic control of DM were younger and following a diet regimen, while those who had poor glycemic control were older and on insulin treatment. Multivariate analysis comprising 415 individuals was conducted to find out the factors that can potentially influence, or may be associated with, the control of DM.

Conclusion: The association of insulin therapy with poor glycemic control is not a cause-effect relationship. Insulin therapy in our study population is underutilized, given the high rate of poor glycemic control and high rate of relative occurrence of complication among the Saudi diabetic population. There is a need to address the importance of maintaining good glycemic control, and the reason for the low rate of insulin users. Close periodic monitoring of glycemic control, utilizing laboratories and home glucose monitoring devices, is required. Effective implementation of these measures, in addition to diabetes education, will have an impact on the future outcome of the Saudi diabetic population.

Download full-text PDF

Source
http://dx.doi.org/10.5144/0256-4947.1998.109DOI Listing

Publication Analysis

Top Keywords

glycemic control
56
poor glycemic
24
diabetic patients
16
good glycemic
16
diabetic population
16
control
15
glycemic
14
saudi diabetic
12
pattern factors
8
factors associated
8

Similar Publications

ACUTE HYPERGLYCEMIA INDUCES PODOCYTE APOPTOSIS BY MONOCYTE TNF-α RELEASE, A PROCESS ATTENUATED BY VITAMIN D AND GLP-1 RECEPTOR AGONISTS.

J Steroid Biochem Mol Biol

January 2025

Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA; Department of Medicine, VA Medical Center, St. Louis, MO, USA; Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA. Electronic address:

Targeting optimal glycemic control based on hemoglobin A1c (A1c) values reduces but does not abolish the onset of diabetic kidney disease and its progression to chronic kidney disease (CKD). This suggests that factors other than the average glucose contribute to the residual risk. Vitamin D deficiency and frequent episodes of acute hyperglycemia (AH) are associated with the onset of albuminuria and CKD progression in diabetes.

View Article and Find Full Text PDF

Saffron has been traditionally used for various health benefits, but its effects on biomarkers of liver function, kidney function, and blood pressure in diabetes are not well understood. This meta-analysis aims to evaluate the impact of saffron supplementation on systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), liver enzymes (ALT, AST), and kidney function markers (BUN, creatinine) in patients with diabetes and prediabetes. A comprehensive search was conducted across multiple databases to identify randomized controlled trials (RCTs) assessing saffron/crocin supplementation on glycemic control, hepatic and renal function, and blood pressure regulation in patients with diabetes and prediabetes.

View Article and Find Full Text PDF

Phenolic acid-rich fraction from Anisopus mannii (PhAM) contains abundance of ferulic acid, gallic acid, protocatechuic acid, and syringic acid. Among other glycolytic enzymes, in vitro, PhAM counteracted the binding of sodium orthovanadate to phosphofructokinase 1 (PFK-1), improving its activities. In a rat model of diet-induced diabetes, PhAM monotherapy reduced HbA1c by an average of 0.

View Article and Find Full Text PDF

Enhancing metformin efficacy with cholecalciferol and taurine in diabetes therapy: Potential and limitations.

World J Diabetes

January 2025

Department of Anatomy, Division of Human Biology, School of Medicine, IMU University, Kuala Lumpur 57000, Malaysia.

Diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), poses a significant global health challenge. Traditional management strategies primarily focus on glycemic control; however, there is a growing need for comprehensive approaches addressing the complex pathophysiology of diabetes complications. The recent study by Attia explores the potential of a novel therapy combining metformin with cholecalciferol (vitamin D3) and taurine to mitigate T2DM-related complications in a rat model.

View Article and Find Full Text PDF

Current perspectives and the future of disease-modifying therapies in type 1 diabetes.

World J Diabetes

January 2025

Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, United Kingdom.

Use of immunomodulating agents to prevent the progression of autoimmune β-cell damage leading to type 1 diabetes mellitus (T1DM) is an interesting area for research. These include non-specific anti-inflammatory agents, immunologic vaccination and anti-inflammatory agents targeting specific immune cells or cytokines. Teplizumab is an anti-CD3-molecule that binds to and leads to the disappearance of the CD3/TCR complex and rendering the T cell anergic to its target antigen.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!